Clinical Scorecard: Could Stool Enzyme Activity Signal IBD?

At a Glance

Key Highlights

• Development of a chemiluminescence-based stool assay to measure GzmA activity
• GzmA activity correlates with intestinal inflammation and T cell activity
• Assay may complement existing tests like fecal calprotectin
• Higher stool GzmA activity observed in IBD patients compared to healthy controls
• Further validation needed for clinical use across IBD phenotypes

Guideline-Based Recommendations

Diagnosis

• Current diagnosis relies on endoscopy, histopathology, and laboratory tests

Management

• Activity-based stool biomarkers may assist in monitoring disease biology

Monitoring & Follow-up

• GzmA activity could provide insights when symptoms and other test results are incongruent

Risks

• Assay is in research stage and does not replace histologic evaluation

Patient & Prescribing Data

Individuals with IBD and healthy controls

GzmA activity may reflect immune activity and inflammation in the gut

Clinical Best Practices

• Utilize existing diagnostic methods while considering new biomarkers
• Monitor IBD patients with a combination of tests for comprehensive assessment
• Stay updated on validation studies for new diagnostic tools

Related Resources & Content

• Nature Biomedical Engineering